STOCKHOLM, SWEDEN–( EMWNews – April 8, 2008) – Scandinavian Clinical Nutrition

(SCN) (Ticker: SCN) signed a world-wide license agreement for the

patent rights to the obesity related virus adenovirus 36 (AD36). The

agreement is signed between SCN and the internationally renowned researcher

and professor Richard

L. Atkinson. In conjunction with the agreement, SCN has initiated

additional research cooperation with Karolinska Institutet in Stockholm,

one of Europe’s leading medical universities, and Professor Atkinson. SCN

aims for a commercial launch of its first diagnostic tests within six to

twelve months.

Atkinson says, “The results from a number of research projects indicate

that between 30 and 57 percent of obese people and as much as 18 percent of

lean people could be infected by the human adenovirus AD36.”

Results from animal testing show that nearly all individuals infected by

the virus had significantly more fat compared with a control group of lean

animals, even though their food intake was in fact less.

“The virus transforms ordinary cells into fat producing cells. It is,

therefore, of utmost importance that we develop reliable screening tests to

identify people who are infected by the virus, and that we also combine

this with efficient treatment,” said Akinson.

Martin Schalling, Professor of Medical Genetics at Karolinska Institutet, says, “On the basis of

the research results so far, we find it highly likely that the AD36 is an

important factor in the epidemic and global development of obesity, which

is one of the biggest and fastest growing public health concerns of our

time. We look forward to taking an active role in this critical field of

research.”

In conjunction with these agreements, SCN has established a subsidiary

called Scandivir AB. SCN owns 71 percent of the shares in Scandivir AB,

while Professor Atkinson, through his company

Obetech, owns 25 percent and the remaining 4 percent are held by three

smaller investors. The purpose of Scandivir AB is to develop diagnostic

screening tests for both hospitals and private use. The screening tests

should easily show if a person either carries AD36 or has developed

antibodies. Further, the purpose is also to develop different types of

treatment such as diets and preparations.

Ulf Söderberg, CEO of SCN, says, “Given the research conducted by Professor

Atkinson and Karolinska Institutet, we see enormous potential in the field

of diagnosis and treatment of

virus-induced obesity. Our vision is that everyone is tested for the

virus and that diagnostic tests are standard at hospitals and health care

centers world-wide.”

SCN has previously announced a license agreement for the substance NGNA as

potential treatment of AD36. Scandivir AB will continue the development of

this substance against AD36 and other viruses.

The estimated investment need for SCN to develop diagnostic tests for

commercial launch is limited to no more than US $2 million. Prior to the

commercial launch, SCN will look to contact corporate partners. Any

additional funding needs will be met through the capitalization of

Scandivir AB.

Background material, high-resolution images, a web-cast from today’s press

conference and clinical studies are available at www.scnutrition.com/press.

Scandinavian Clinical Nutrition AB (publ) works in R&D and sales of

scientifically documented products within the field of nutrition

(nutraceuticals). Established in 2006, SCN maintains a product portfolio

with established trademarks, such as CUUR, Coldizin, Immulina and Ledactin. Core

competence and strategic alliances within both R&D and sales, in

combination with innovative and scientifically documented products, create

the right conditions for profitable growth on the international market. The

shares of SCN are traded under the ticker “SCN” on Oslo Axess

(www.osloaxess.no) and NGM Equity (www.ngm.se).